Carol Peña Selected Research

copanlisib

12/2020	Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
1/2020	Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
1/2020	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
12/2017	Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carol Peña Research Topics

Disease

9	Neoplasms (Cancer) 01/2021 - 10/2010
4	Exanthema (Rash) 01/2020 - 08/2009
3	Thyroid Neoplasms (Thyroid Cancer) 01/2017 - 07/2014
3	Fatigue 01/2017 - 08/2009
2	Diarrhea 01/2020 - 12/2015
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2015 - 01/2012
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Stomatitis 01/2020
1	Acute Coronary Syndrome 01/2018
1	Lymphoma (Lymphomas) 12/2017
1	Headache (Headaches) 01/2017
1	Thyrotoxicosis 01/2017
1	Alopecia (Baldness) 07/2014
1	Disease Progression 07/2014
1	Kidney Neoplasms (Kidney Cancer) 10/2010
1	Renal Cell Carcinoma (Grawitz Tumor) 10/2010
1	Breast Neoplasms (Breast Cancer) 08/2009

Drug/Important Bio-Agent (IBA)

9	Sorafenib (BAY 43-9006)FDA Link 01/2018 - 08/2009
4	copanlisibIBA 12/2020 - 12/2017
3	Alanine Transaminase (SGPT)IBA 01/2020 - 01/2017
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 10/2010
3	Pharmaceutical PreparationsIBA 01/2017 - 08/2009
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2020 - 01/2020
2	N- (3,4- difluoro- 2- (2- fluoro- 4- iodophenylamino)- 6- methoxyphenyl)- 1- (2,3- dihydroxypropyl)cyclopropane- 1- sulfonamideIBA 12/2020 - 01/2020
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020 - 12/2017
2	IodineIBA 01/2017 - 07/2014
2	Blood Proteins (Serum Proteins)IBA 01/2012 - 10/2010
1	TabletsIBA 01/2021
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021
1	BAY 1436032IBA 01/2021
1	Drug CombinationsIBA 01/2020
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020
1	eribulin FDA Link 01/2018
1	Protein Isoforms (Isoforms)IBA 12/2017
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2017
1	Triiodothyronine (Liothyronine)FDA LinkGeneric 01/2017
1	Glutamate DehydrogenaseIBA 01/2017
1	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2017
1	ErbB Receptors (EGF Receptor)IBA 12/2015
1	Circulating Tumor DNAIBA 12/2015
1	Dacarbazine (DIC)FDA LinkGeneric 04/2014
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2010
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2010
1	Carbonic Anhydrase IXIBA 10/2010
1	Tissue Inhibitor of Metalloproteinase-1IBA 10/2010

Therapy/Procedure

1	Therapeutics 12/2017
1	Drug Therapy (Chemotherapy) 08/2009